Latest news from Alzheimer's Drug Discovery Foundation on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/dr-jeffrey-cummings-wins-alzheimer-s-drug-discovery-foundation-s-addf-prestigious-melvin-r-goodes-prize/?sc=rsin /articles/dr-jeffrey-cummings-wins-alzheimer-s-drug-discovery-foundation-s-addf-prestigious-melvin-r-goodes-prize/?sc=rsin Tue, 17 Sep 2019 13:05:45 EST Dr. Jeffrey Cummings, a world-renowned Alzheimer's researcher and leader in clinical trials, has been named the recipient of the 2019 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery. The prize, awarded by the Alzheimer's Drug Discovery Foundation (ADDF), recognizes leading researchers developing treatments for Alzheimer's disease and related dementias. Alzheimer's Drug Discovery Foundation /articles/the-alzheimer-s-drug-discovery-foundation-addf-announces-the-final-program-of-its-20th-international-conference-on-alzheimer-s-drug-discovery/?sc=rsin /articles/the-alzheimer-s-drug-discovery-foundation-addf-announces-the-final-program-of-its-20th-international-conference-on-alzheimer-s-drug-discovery/?sc=rsin Thu, 08 Aug 2019 12:05:02 EST The 20th International Conference on Alzheimer's Drug Discovery, a two-day interdisciplinary forum to be held September 16-17, 2019 in Jersey City, NJ Alzheimer's Drug Discovery Foundation /articles/alzheimer-s-drug-discovery-foundation-announces-new-research-initiative-to-advance-digital-tools-for-detection-of-alzheimer-s-and-related-dementias/?sc=rsin /articles/alzheimer-s-drug-discovery-foundation-announces-new-research-initiative-to-advance-digital-tools-for-detection-of-alzheimer-s-and-related-dementias/?sc=rsin Tue, 02 Apr 2019 13:30:51 EST As part of its Diagnostics Accelerator research program, the Alzheimer's Drug Discovery Foundation (ADDF) announced today a new initiative that aims to fast-track the development of digital tools for Alzheimer's disease and related dementias. Alzheimer's Drug Discovery Foundation /articles/the-alzheimer-s-drug-discovery-foundation-s-diagnostics-accelerator-initiative-expands-its-focus-on-frontotemporal-degeneration/?sc=rsin /articles/the-alzheimer-s-drug-discovery-foundation-s-diagnostics-accelerator-initiative-expands-its-focus-on-frontotemporal-degeneration/?sc=rsin Thu, 03 Jan 2019 10:05:45 EST The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator initiative has announced a new $5 million commitment to projects targeting the development of biomarkers for frontotemporal degeneration (FTD), the most common dementia for people under 60. Alzheimer's Drug Discovery Foundation /articles/new-generation-of-therapeutics-based-on-understanding-of-aging-biology-show-promise-for-alzheimer's-disease/?sc=rsin /articles/new-generation-of-therapeutics-based-on-understanding-of-aging-biology-show-promise-for-alzheimer's-disease/?sc=rsin Mon, 10 Dec 2018 15:05:52 EST A scientific strategy that explores therapeutic targets based on the biology of aging is gaining ground as an effective approach to prevent and treat Alzheimer's disease, according to research published in the December 7, 2018 online issue of Neurology(r). Alzheimer's Drug Discovery Foundation /articles/the-alzheimer's-drug-discovery-foundation-statement:-justice-sandra-day-o'connor's-announcement-of-dementia-diagnosis/?sc=rsin /articles/the-alzheimer's-drug-discovery-foundation-statement:-justice-sandra-day-o'connor's-announcement-of-dementia-diagnosis/?sc=rsin Wed, 24 Oct 2018 08:05:11 EST The Alzheimer's Drug Discovery Foundation (ADDF) is saddened to hear the news that former Supreme Court Justice Sandra Day O'Connor released a letter today saying she has been diagnosed with the beginning stages of dementia, probably Alzheimer's disease. Alzheimer's Drug Discovery Foundation /articles/19th-annual-conference-on-alzheimer's-drug-discovery-highlights-multiple-approaches-to-prevent-and-treat-alzheimer's-disease/?sc=rsin /articles/19th-annual-conference-on-alzheimer's-drug-discovery-highlights-multiple-approaches-to-prevent-and-treat-alzheimer's-disease/?sc=rsin Fri, 21 Sep 2018 09:15:42 EST Nearly 200 academic and industry researchers gathered this week to share updates on preclinical and clinical-stage Alzheimer's disease research at the 19th International Conference on Alzheimer's Drug Discovery. The two-day conference, organized by the Alzheimer's Drug Discovery Foundation (ADDF), focused on gene therapy and alternative modalities for neurodegenerative diseases, progress in developing novel drugs to treat Alzheimer's disease (AD) and related dementias, as well as the need for new biomarkers. Alzheimer's Drug Discovery Foundation /articles/dr.-michela-gallagher-wins-alzheimer's-drug-discovery-foundation's-prestigious-melvin-r.-goodes-prize/?sc=rsin /articles/dr.-michela-gallagher-wins-alzheimer's-drug-discovery-foundation's-prestigious-melvin-r.-goodes-prize/?sc=rsin Mon, 17 Sep 2018 09:00:00 EST Prize recognizes Dr. Gallagher's contributions in the field of Alzheimer's research in academia and through her groundbreaking therapeutics company, AgeneBio Alzheimer's Drug Discovery Foundation /articles/-new-coalition-of-philanthropists-including-bill-gates-and-leonard-lauder-commit-more-than-30-million-to-develop-new-tools-to-diagnose-alzheimer's-disease/?sc=rsin /articles/-new-coalition-of-philanthropists-including-bill-gates-and-leonard-lauder-commit-more-than-30-million-to-develop-new-tools-to-diagnose-alzheimer's-disease/?sc=rsin Tue, 17 Jul 2018 13:20:19 EST Philanthropist Bill Gates and the Alzheimer's Drug Discovery Foundation (ADDF) co-founder Leonard Lauder have announced a new initiative, Diagnostics Accelerator, to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias. Alzheimer's Drug Discovery Foundation /articles/new-report-highlights-innovation-in-alzheimer-s-clinical-trials/?sc=rsin /articles/new-report-highlights-innovation-in-alzheimer-s-clinical-trials/?sc=rsin Wed, 01 Nov 2017 09:10:47 EST Alzheimer's Drug Discovery Foundation Releases Comprehensive Survey of Clinical-Stage Alzheimer's Drugs Alzheimer's Drug Discovery Foundation /articles/innovative-alzheimer-s-disease-combination-therapy-trial-supported-by-new-joint-funding-initiative/?sc=rsin /articles/innovative-alzheimer-s-disease-combination-therapy-trial-supported-by-new-joint-funding-initiative/?sc=rsin Tue, 24 Oct 2017 09:20:53 EST The Alzheimer's Association and Alzheimer's Drug Discovery Foundation (ADDF) are collaborating to jointly fund a new combination therapy clinical trial for Alzheimer's disease to be conducted by Amylyx Pharmaceuticals. The $1.85 million grant is the first award under an initiative created by the Alzheimer's Association and the ADDF to fund combination therapies. Alzheimer's Drug Discovery Foundation /articles/alzheimer-s-drug-discovery-foundation-and-pfizer-s-centers-for-therapeutic-innovation-co-fund-new-alzheimer-s-project/?sc=rsin /articles/alzheimer-s-drug-discovery-foundation-and-pfizer-s-centers-for-therapeutic-innovation-co-fund-new-alzheimer-s-project/?sc=rsin Tue, 03 Oct 2017 09:30:14 EST Cross-Sector Collaboration Aimed at Speeding the Development of Potential Therapies That May Protect Brain Cells Alzheimer's Drug Discovery Foundation /articles/dr-roberta-diaz-brinton-wins-alzheimer-s-drug-discovery-foundation-s-melvin-r-goodes-prize/?sc=rsin /articles/dr-roberta-diaz-brinton-wins-alzheimer-s-drug-discovery-foundation-s-melvin-r-goodes-prize/?sc=rsin Thu, 14 Sep 2017 09:55:30 EST Dr. Brinton Has Pioneered a Promising Neurogenesis Therapy for Alzheimer's Alzheimer's Drug Discovery Foundation /articles/18th-annual-conference-on-alzheimers-drug-discovery-showcases-non-amyloid-research/?sc=rsin /articles/18th-annual-conference-on-alzheimers-drug-discovery-showcases-non-amyloid-research/?sc=rsin Wed, 13 Sep 2017 11:05:12 EST /PRNewswire-USNewswire/ -- Nearly 200 academic and industry researchers came together to share updates on preclinical and clinical-stage Alzheimer's disease research at the 18th Annual Conference on Alzheimer's Drug Discovery. The two-day conference, organized by the Alzheimer's Drug Discovery Foundation (ADDF), is the first and only to focus solely on non-amyloid drug programs in development. Alzheimer's Drug Discovery Foundation /articles/the-alzheimers-drug-discovery-foundation-and-science-exchange-launch-addf-access-to-advance-cns-research/?sc=rsin /articles/the-alzheimers-drug-discovery-foundation-and-science-exchange-launch-addf-access-to-advance-cns-research/?sc=rsin Wed, 07 Jun 2017 10:20:43 EST /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF), the only public charity solely focused on funding the development of drugs for Alzheimer's, and Science Exchange today announced the launch of ADDF ACCESS, a first-of-its-kind online platform designed to match scientists working on central nervous system (CNS) diseases with a vetted network of contract research organizations (CROs). Alzheimer's Drug Discovery Foundation /articles/alzheimer-s-drug-discovery-foundation-launches-expanded-brain-health-and-dementia-prevention-website/?sc=rsin /articles/alzheimer-s-drug-discovery-foundation-launches-expanded-brain-health-and-dementia-prevention-website/?sc=rsin Thu, 27 Oct 2016 10:05:42 EST The Alzheimer's Drug Discovery Foundation (ADDF) announced today the relaunch of CognitiveVitality.org, its brain health and dementia prevention website. The streamlined, easy-to-navigate site separates fact from fiction and empowers people to make smarter choices for their brain health. Alzheimer's Drug Discovery Foundation /articles/new-clinical-trial-will-test-cancer-drug-as-alzheimer-s-treatment/?sc=rsin /articles/new-clinical-trial-will-test-cancer-drug-as-alzheimer-s-treatment/?sc=rsin Thu, 29 Sep 2016 08:00:27 EST The Alzheimer's Drug Discovery Foundation (ADDF) announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna(r) for use as a cancer therapy) in patients with Alzheimer's disease. Alzheimer's Drug Discovery Foundation /articles/dr-d-martin-watterson-wins-alzheimer-s-drug-discovery-foundation-s-second-melvin-r-goodes-prize-for-excellence-in-alzheimer-s-drug-discovery/?sc=rsin /articles/dr-d-martin-watterson-wins-alzheimer-s-drug-discovery-foundation-s-second-melvin-r-goodes-prize-for-excellence-in-alzheimer-s-drug-discovery/?sc=rsin Tue, 13 Sep 2016 13:00:00 EST Medicinal chemist and pharmacologist Daniel Martin Watterson, PhD, has been named the second annual winner of the Alzheimer's Drug Discovery Foundation's (ADDF) Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery. The prize is the first to specifically recognize researchers working in promising areas of drug discovery for Alzheimer's disease and related dementias. Dr. Watterson is the John G. Searle Professor of Molecular Biology and Biochemistry and Professor of Pharmacology at Northwestern University's Feinberg School of Medicine. He also serves in an advisory role to pharmaceutical and biotechnology companies. Alzheimer's Drug Discovery Foundation /articles/psychogenics-and-the-alzheimers-drug-discovery-foundation-announce-a-risk-sharing-partnership-for-preclinical-studies/?sc=rsin /articles/psychogenics-and-the-alzheimers-drug-discovery-foundation-announce-a-risk-sharing-partnership-for-preclinical-studies/?sc=rsin Tue, 12 Jan 2016 11:05:48 EST /PRNewswire-USNewswire/ -- PsychoGenics Inc. and the Alzheimer's Drug Discovery Foundation (ADDF) announce a new partnership to bring PsychoGenics' validated Alzheimer's animal models and experimental services to ADDF grantees working on preclinical Alzheimer's drug discovery programs. Through the partnership, PsychoGenics will establish risk-sharing agreements with ADDF-funded biotechnology companies to make its services available under extremely favorable financial terms, thus increasing the value of the ADDF's grants. Alzheimer's Drug Discovery Foundation /articles/hundreds-of-scientists-gather-to-hear-latest-alzheimer-s-drug-discovery-preclinical-and-clinical-study-results/?sc=rsin /articles/hundreds-of-scientists-gather-to-hear-latest-alzheimer-s-drug-discovery-preclinical-and-clinical-study-results/?sc=rsin Mon, 05 Oct 2015 08:30:00 EST More than 100 of the world's leading Alzheimer's drug researchers will gather today and tomorrow at the Hyatt Regency Jersey City to hear the latest developments in the discovery and testing of promising drugs, detection technologies, biomarkers and newly discovered therapeutic targets for preventing, treating and curing Alzheimer's disease and related dementias. Organized and hosted by the Alzheimer's Drug Discovery Foundation, the conference is the only scientific meeting dedicated solely to bringing leading academic and industry scientists together to present new research on Alzheimer's drug discovery and establish partnerships to further their studies. Alzheimer's Drug Discovery Foundation